Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled, Escalating Single Dose, Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

NCT05298813 is registered in ClinicalTrials.gov with Immune Biosolutions Inc as lead sponsor.

NCT NCT05298813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05298813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled, Escalating Single Dose, Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
Lead sponsor
Immune Biosolutions Inc
Phase
Phase 1/2
Overall status
Completed
Start date
September 29, 2021
Completion date
January 4, 2023
Enrollment
162 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19